Recently, the Vasculitis Foundation, in collaboration with a group of physicians and vasculitis investigators in the U.S. and Latin America (i.e., Mexico, Colombia, Peru, Chile and Argentina), launched an educational series of videos in Spanish called, Aprendiendo de Vasculitis. “The goal of these videos is to provide education to all Spanish-speaking patients,” explains Sebastian E….
Updated research on the complexities of central nervous system (CNS) lupus, as well as its diagnosis and treatment are discussed.
Defined by the presence of antiphospholipid antibodies (aPL) in individuals with clinical evidence of thrombosis or pregnancy morbidity, antiphospholipid syndrome (APS) is a systemic autoimmune thrombophilia. Clinical thrombosis, which should be confirmed by objective validated criteria (e.g., imaging studies or histopathology), can occur in the arterial, venous or small vessel vasculature and is not limited…
Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…
A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
Granulomatosis with polyangiitis (GPA) is a type of anti-neutrophil cytoplasmic antibody (ANCA) associated small vessel vasculitis that typically affects the kidneys, lungs and sinuses.1 Due to an overlap in signs and symptoms, GPA may initially be difficult to distinguish from IgG4-related disease, another condition that can affect multiple tissues and has variable presentations. Further complicating…
A minority of patients experience lingering symptoms after infection with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the different presentations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leadership role in managing patients with the illness and contributing to this important research…
Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.
Rheumatologists are often called upon to see patients with unexplained symptoms and mysterious illnesses and to manage disease, sometimes with a dearth of evidence. Patients in rheumatology practices also tend to explore treatment modalities outside of the established medical model, sometimes referred to as fringe medicine. Complementary and alternative medicine practices that comprise fringe medicine…
Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.